Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy

Molecular Imaging and Biology

Volumn 11, Issue 3, 2009, Pages 159-166

  Pan, Mei Hsiu ^a   Gao, Dong Wei ^a   Feng, Jinjin ^a   He, Jiang ^a   Seo, Youngho ^a   Tedesco, John ^b   Wolodzko, John G ^b   Hasegawa, Bruce H ^a   Franc, Benjamin L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Cytogen Corporation   (United States)

Author keywords

Bioluminescence imaging; Immunoscintigraphy; Indium 111; Lutetium 177; Prostate cancer; Prostate specificmembrane antigen; Radioimmunotherapy

Indexed keywords

ACETIC ACID DERIVATIVE; ANTIBODY CONJUGATE; CAPROMAB PENDETIDE IN 111; INDIUM 111; LUTETIUM 177; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7E11; MONOCLONAL ANTIBODY 7E11 IN 111; MONOCLONAL ANTIBODY 7E11 LU 177; PENTETIC ACID DERIVATIVE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; INDIUM; LUTETIUM; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; AUTORADIOGRAPHY; CELL STRAIN LNCAP; CONTROLLED STUDY; DOSIMETRY; DRUG UPTAKE; DRUG USE; GAMMA SCINTIGRAPHY; ISOTOPE LABELING; LYMPH NODE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION MEASUREMENT; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; ANIMAL; DRUG SCREENING; HUMAN; IMMUNOLOGY; LIVER; METABOLISM; METHODOLOGY; PROSTATE TUMOR;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; LIVER; LUTETIUM; MALE; MICE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67349162448     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-008-0185-9     Document Type: Article

References (23)

1. Swanson GP, Thompson IM, Basler J (2006) Current status of lymph node-positive prostate cancer: Incidence and predictors of outcome. Cancer 107:439-450
2. Swanson GP, Thompson IM, Basler J (2006) Treatment options in lymph node-positive prostate cancer. Cancer 106:2531-2539
3. Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109
4. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23:4591-4601
5. Russell PJ, Hewish D, Carter T et al (2004) Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: In vitro and in vivo studies. Cancer Immunol Immunother 53:411-421
6. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH (2000) In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 60:5237-5243
7. Wright GL Jr, Grob BM, Haley C et al (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326-334
8. Fair WR, Israeli RS, Heston WD (1997) Prostate-specific membrane antigen. Prostate 32:140-148
9. Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH (2006) Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 26:5310-5324
10. Troyer JK, Beckett ML, Wright GL Jr (1995) Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62:552-558
11. Troyer JK, Beckett ML, Wright GL Jr (1997) Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30:232-242
12. Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7:927-935
13. Barren RJ 3rd, Holmes EH, Boynton AL, Misrock SL, Murphy GP (1997) Monoclonal antibody 7E11.C5 staining of viable LNCaP cells. Prostate 30:65-68
14. Elgamal AA, Troychak MJ, Murphy GP (1998) ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: Analysis of 136 scans of 100 patients. Prostate 37:261-269
15. Feneley MR, Jan H, Granowska M et al (2000) Imaging with prostate-specific membrane antigen (PSMA) in prostate cancer. Prostate Cancer Prostatic Dis 3:47-52
16. Tedesco J, Goeckeler W, Becker M, Frank K, Gulyas G, Young S (2005) Development of optimal Lu-177 labeled monoclonal antibody (7E11) construct (CYT-500) for radioimmunotherapy of hormone refractory prostate cancer. J Clin Oncol 23(16S):4765
17. Tedesco J, Wolodzco J, Goeckeler W, Becker M, Hasegawa B, Franc B (2006) Development and characterization of a novel 177Lu-MeO-DOTA-7E11 antibody construct (CYT-500) for the treatment and imaging of prostate adenocarcinoma. AACR Annual Meeting
18. Nargund V, Al Hashmi D, Kumar P et al (2005) Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: Comparison with clinical, surgical and histological staging. BJU Int 95:1232-1236
19. Christiansen JJ, Rajasekaran SA, Inge L, Cheng L, Anilkumar G, Bander NH, Rajasekaran AK (2005) N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy. Mol Cancer Ther 4:704-714
20. Bander NH, Trabulsi EJ, Kostakoglu L et al (2003) Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 170:1717-1721
21. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH (2004) Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22:2522-2531
22. O'Donoghue JA, Bardies M, Wheldon TE (1995) Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36:1902-1909
23. Seo Y, Wong KH, Sun M, Franc BL, Hawkins RA, Hasegawa BH (2005) Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system. J Nucl Med 46:868-877